Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.45 |
| ▸ | PTPRB | P23467 | 2/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 3/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154058 | 0.95 | PTPN1 (0.41) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL4958087 | 0.93 | PTPN1 (0.40) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL6155070 | 0.85 | PTPN5 (0.45) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL4955383 | 0.81 | PTPN1 (0.43) | PTPN1PTPN2PTPRCNPC1 | |
| SCHEMBL6154059 | 0.79 | PTGES (0.40) | GAANPC1LMNAHPGDHSD17B10 | |
| SCHEMBL5506735 | 0.76 | PTPN1 (0.43) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL5502775 | 0.74 | PTPN1 (0.44) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL4956777 | 0.72 | PTPN1 (0.41) | PTPN1PTPN2PTPRCNPC1LMNA | |
| SCHEMBL4955386 | 0.72 | NR3C1 (0.39) | GAANPC1LMNAHPGDHSD17B10 | |
| SCHEMBL4958895 | 0.71 | PTGES (0.57) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | IMPINJ, INC. | 2008-08-21 | — | — | US | claimed |
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-08-31 | — | — | US | claimed |
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | IMPINJ, INC. | 2008-08-21 | — | — | US | disclosed |
| US-7381736-B2 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1841749-A1 | DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | Metabasis Therapeutics, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2006028970-A1 | DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | PTPN1, PTPN5, PTPN18 | PTPN1 1/4885PTPN2 6/4885PTPRB 25/4885 |
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | PTPN1, PTPN5, PTPN18 | PTPN1 1/4885PTPN2 6/4885PTPRB 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.